One of the challenges of the increased frequency of chest CT scans being done for screening of people at higher risk of lung cancer, or done more commonly for chest symptoms, is that lung nodules are very commonly found, but most the time they aren't cancer.  Most studies show that >90% of lung nodules are benign, but the majority lead to additional work-up, and in nearly 100% of cases, they cause anxiety for the patient. What if a blood test could help clarify the probability that someone doesn't have a lung cancer?

Dr. David Gerber, University of Texas-Southwestern, reviews the results of the PROSE study of the Veristrat serum proteomics test to predict benefit of chemo or EGFR inhibitor for second line treatment of advanced lung cancer.

[powerpress]

We know that many people interested in the topics we discuss in our webinars may not be able to attend the live programs, but we're committed to offering our content to people as easily as possible. Accordingly, here is the podcast version of Dr. Pennell's very well received presentation on a range of molecular markers currently being used and others emerging in clinical trials as potential tools for the coming years.

Below you'll find the audio versions of the presentation.

A few weeks ago I described a blood test for predicting survival after getting an oral epidermal growth factor receptor (EGFR) inhibitor that is just becoming commercially available. This is called the Veristrat test and from company called Biodesix.